Search Results

Neuroscience-focused Rapport Therapeutics and radiopharma developer Telix Pharma announced their respective plans Friday for initial public offerings on the Nasdaq for undisclosed dollar amounts.

AVITA Medical, Inc. announced that the U.S. Food and Drug Administration has approved its premarket approval supplement for the RECELL GO™ System, its next-generation autologous cell harvesting device that harnesses the regenerative properties of a patient’s own skin to treat thermal burn wounds and full-thickness skin defects.

AVITA Medical, Inc., a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, announced that the Joseph M. Still Burn Center at Doctors Hospital of Augusta is the first U.S. burn center to treat a patient using its RECELL GO™ System.

GenomOncology revealed an upgraded version of GO Pathology Workbench, their software platform for tertiary analysis and reporting of next generation sequencing and other molecular testing results.

Soterix Medical Inc., the global leader in non-invasive brain stimulation and synergistic monitoring technologies, announced the launch of MxN-GO EEG, a combined High Definition transcranial Electrical Stimulation and EEG system with a unique untethered design.

Ampio Pharmaceuticals, Inc. announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2023, which was filed on March 27, 2024 with the Securities and Exchange Commission, the audited financial statements contained an unqualified audit opinion from its independent registered public accounting firm that included an explanatory paragraph related to the Company’s ability to continue as a going concern.

Global heart health leader OMRON Healthcare announced an evolution of its Going for Zero mission to eliminate heart attack and stroke with increased focus on atrial fibrillation, expanded education initiatives, and advancement of its digital health transformation to support a healthcare system facing staffing shortages and crisis-level health inequities.

Cassava Sciences, Inc today announced the completion of another interim safety review of simufilam in on-going Phase 3 clinical trials in patients with Alzheimer’s disease.